🔬 IMMUcan at #ESMOImmuno25

New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.

New IMMUcan preprint on early-stage NSCLC just released.

A major multi-institutional effort. Congrats to all contributors! 👏

www.medrxiv.org/content/10.1...

Excited to see the Cellohood preprint out — a big step forward for understanding tumor–immune interactions within IMMUcan.

A great milestone for a strong collaborative effort. Congrats to all co-authors! 👏

🔗 www.biorxiv.org/content/10.1...

Last week, the IMMUcan consortium met at EORTC Brussels (27–28 Oct 2025) for two days of inspiring discussions and data exploration. 💡

Researchers, clinicians & data scientists from across Europe shared results and shaped the next steps in cancer-immune research.

IMMUcan represents collaboration in action.
Clinicians & researchers across Europe are building one of the largest tumour–immune profiling efforts to date.

Together, we’re turning complexity into impact.
Learn more about our consortium: immucan.eu

Spatial transcriptomics = gene activity + location.

In IMMUcan, it shows where tumour & immune cells interact, and how that shapes treatment response. A living map of the tumour microenvironment.

We’re happy to announce that IMMUcan will be showcased at #EPFCongress2025 (26–27 Nov, Brussels)!

Two days of dialogue on patient involvement, equity, resilience, digital health, AMR, and climate & health.
👉 epfcongress.eu

#PatientLeadership

Next week, Henoch Hong brings IMMUcan’s voice to London for the Biomarkers + Precision Medicine 2025 Conference (30 Sept – 1 Oct).

Henoch will share how IMMUcan’s pan-European effort to map immune-oncology biomarkers is driving collaboration to unlock new therapies and deliver personalised care.

New publication alert in Cell Reports Methods!

The IMMUcan consortium is proud to present our latest work on scalable pipelines for large-scale multiplexed imaging (mIF & IMC) in FFPE tumour tissues.

Congratulations to the authors and contributors!
Read the article www.cell.com/cell-reports...

What if we could predict a tumour’s next move?

IMMUcan’s deep look into the tumour microenvironment shows how cancer hides, adapts, resists. Every insight brings us closer to smarter, more resilient therapies.

How do cancers evade the immune system?

IMMUcan is helping decode the mechanisms (antigen presentation loss, immune suppression, dynamic resistance) through spatial & single-cell tech.

Understanding this is key to improving immunotherapy.

What if we could decode what’s happening inside a tumour?

IMMUcan has profiled 2,600+ samples across cancer types using multi-omics tech.

We’re mapping how immune & #cancer cells interact, and what signals shape response or resistance.

We aim to predict what #treatment works for each patient.

In cancer research, personalised medicine is a shift in how we understand disease, deliver care, and define outcomes.

We broke it down in this blog: from biomarkers + big data to what matters most: the patient.

Worth a revisit as IMMUcan’s data continues to grow.
bit.ly/4oyKJpx

Did you know? IMMUcan has profiled 2,600+ tumour samples using multi-omics tech: RNA-seq, proteomics, IHC.

Why? To map the tumour microenvironment in detail.

The goal: smarter, personalised immunotherapy for every patient.

IMMUcan at major oncology congresses in 2025!

It’s been over a year since Franken et al. made the cover of Immunity, and the impact keeps growing.

📖 Revisit the original article here: www.cell.com/issue/S1074-...

More impactful IMMUcan publications coming this year. Stay tuned!

IMMUcan was present at the ASCO 2025 Annual Meeting, taking place from 30 May to 3 June in Chicago.

Dr Athenais van der Elst presented a poster on Mechanisms of resistance to anti-PD1 treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Hello from the IMMUcan team 👋 Last week, we wrapped up our General Assembly. We exchanged on scientific updates and future planning.

Highlights: deep profiling, AI analysis, comms, and sustainability. T

hanks to our hosts & partners!